Regeneron Pharmaceuticals, Inc.

(NASDAQ Global Select)
Back to all articles
Bullish +62

Regeneron Pharmaceuticals stock (US7739031091): Q1 earnings beat with $9.47 EPS - AD HOC NEWS

AI-generated analysis

πŸ“ˆ Regeneron reported Q1 2026 EPS of $9.47, beating analyst estimates of $8.91 by $0.56.

πŸ’° Quarterly revenue reached $3.61 billion, a 19% year-over-year increase exceeding the $3.48 billion estimate.

πŸ“‰ Stock price was $719.88 on May 14, trading below its 50-day moving average of $747.55.

πŸ’Š Core products Eylea and Dupixent continue to drive significant revenue growth for the company.

πŸ”¬ Trailing twelve-month EPS stands at $41.04 with net income of $4.50 billion reported.

πŸš€ Future EPS is projected to grow 11.89% to $41.51 per share in the next year.

🀝 Strategic collaboration with Sanofi on Dupixent remains a major growth driver for the firm.

🧬 Company utilizes VelociSuite technology and genetic insights to develop medicines for serious diseases.

⚠️ Eylea faces biosimilar pressure, though oncology expansions like Libtayo provide resilience.

πŸ₯ Regeneron operates from Tarrytown, New York, with a pipeline in oncology, neuroscience, and rare diseases.

Bullish Signals
  • Regeneron significantly beat Q1 earnings estimates with EPS of $9.47 versus the consensus of $8.91.
  • Revenue grew 19% year-over-year to $3.61 billion, demonstrating strong top-line momentum.
  • The company's trailing twelve-month net income reached $4.50 billion with an EPS of $41.04.
  • Analysts project a healthy 11.89% growth in future EPS to reach $41.51 per share next year.
  • Core franchises Eylea and Dupixent are delivering robust sales despite competitive market pressures.
  • Strategic partnership with Sanofi on Dupixent continues to be a major driver of revenue expansion.
Risk Factors
  • The stock is trading below its 50-day moving average ($719.88 vs $747.55), indicating recent price weakness.
  • Key product Eylea faces increasing pressure from biosimilar competition in the retinal disease market.
  • The broader biotech sector faces ongoing challenges including patent cliffs and intense competitive dynamics.
Full Analysis
Regeneron Pharmaceuticals reported first-quarter 2026 earnings on April 29, significantly beating analyst expectations with earnings per share of $9.47 compared to a consensus of $8.91. The company generated quarterly revenue of $3.61 billion, representing a 19% year-over-year increase and surpassing estimates of $3.48 billion. This strong performance was driven by robust demand for its core franchises, particularly Eylea and Dupixent, which continue to serve as primary revenue generators despite competitive pressures in the biotech sector. The stock traded at $719.88 on May 14, 2026, trading below its 50-day moving average of $747.55 and 200-day average of $744.35. On a trailing twelve-month basis, Regeneron achieved an EPS of $41.04 with net income reaching $4.50 billion. Analysts project future earnings per share to grow by 11.89% to $41.51 in the coming year, reflecting confidence in the company's diversified pipeline spanning oncology, neuroscience, and rare diseases. Regeneron's business model relies on genetic insights and advanced technologies like VelociSuite to develop biologic medicines for serious conditions. Key products include Eylea for retinal diseases and Dupixent, co-developed with Sanofi, which targets atopic dermatitis and asthma. While the company faces industry-wide challenges such as patent cliffs and biosimilar competition, its strong R&D investment and strategic partnerships position it well for continued growth in precision medicine.